Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin.
Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin.
复制标题
DOI：
10.3748/wjg.v29.i8.1359
复制
发表时间：
2023-02-28
影响因子：
4.3
通讯作者：
Pan WD
中科院分区：
文献类型：
--
作者：
Qian XJ;Wen ZM;Huang XM;Feng HJ;Lin SS;Liu YN;Li SC;Zhang Y;Peng WG;Yang JR;Zheng ZY;Zhang L;Zhang DW;Lu FM;Liu LJ;Pan WD
Serum protein induced by vitamin K absence or antagonist-II (PIVKA-II) is a promising biomarker for hepatocellular carcinoma (HCC) surveillance. To identify the contributing factors related to the abnormal elevation of PIVKA-II level and assess their potential influence on the performance of PIVKA-II in detecting HCC. This study retrospectively enrolled in 784 chronic liver disease (CLD) patients and 267 HCC patients in Mengchao Hepatobiliary Hospital of Fujian Medical University from April 2016 to December 2019. Logistic regression and the area under the receiver operating characteristic curve (AUC) were used to evaluate the influencing factors and diagnostic performance of PIVKA-II for HCC, respectively. Elevated PIVKA-II levels were independently positively associated with alcohol-related liver disease, serum alkaline phosphatase (ALP), and total bilirubin (TBIL) for CLD patients and aspartate aminotransferase (AST) and tumor size for HCC patients (all P < 0.05). Serum PIVKA-II were significantly lower in patients with viral etiology, ALP ≤ 1 × upper limit of normal (ULN), TBIL ≤ 1 × ULN, and AST ≤ 1 × ULN than in those with nonviral disease and abnormal ALP, TBIL, or AST (all P < 0.05), but the differences disappeared in patients with early-stage HCC. For patients with TBIL ≤ 1 × ULN, the AUC of PIVKA-II was significantly higher compared to that in patients with TBIL > 1 × ULN (0.817 vs 0.669, P = 0.015), while the difference between ALP ≤ 1 × ULN and ALP > 1 × ULN was not statistically significant (0.783 vs 0.729, P = 0.398). These trends were then more prominently perceived in subgroups of patients with viral etiology and HBV alone. Serum PIVKA-II has better performance in detecting HCC at an early stage for CLD patients with normal serum TBIL.
登录
查看更多内容
影响因子：
2.5
作者：
Qian X;Liu S;Long H;Zhang S;Yan X;Yao M;Zhou J;Gong J;Wang J;Wen X;Zhou T;Zhai X;Xu Q;Zhang T;Chen X;Hu G;Wang J;Gao Z;Nan Y;Chen J;Hu B;Zhao J;Lu F
通讯作者：
Lu F
DOI：
10.1111/j.1530-0277.1986.tb05167.x
发表时间：
1986-12-01
期刊：
ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH
影响因子：
--
作者：
IBER, FL;SHAMSZAD, M;JACOB, R
通讯作者：
JACOB, R
影响因子：
3.4
作者：
Kang, Keunhee;Kim, Ji Hoon;Byun, Kwan Soo
通讯作者：
Byun, Kwan Soo
影响因子：
25.7
作者：
Pote, Nicolas;Cauchy, Franois;Paradis, Valerie
通讯作者：
Paradis, Valerie
索拉非尼对亚太地区晚期肝细胞癌患者的疗效和安全性：一项 III 期随机、双盲、安慰剂对照试验
影响因子：
51.1
作者：
Cheng, Ann-Lii;Kang, Yoon-Koo;Guan, Zhongzhen
通讯作者：
Guan, Zhongzhen